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Abstract
Emergency departments are a major entry point for the initial management of acute heart failure (AHF) patients 
throughout the world. The initial diagnosis, management and disposition – the decision to admit or discharge – of AHF 
patients in the emergency department has significant downstream implications. Misdiagnosis, under or overtreatment, or 
inappropriate admission may place patients at increased risk for adverse events, and add costs to the healthcare system. 
Despite the critical importance of initial management, data are sparse regarding the impact of early AHF treatment 
delivered in the emergency department compared to inpatient or chronic heart failure management. Unfortunately, 
outcomes remain poor, with nearly a third of patients dying or re-hospitalised within 3 months post-discharge. In the 
absence of robust research evidence, consensus is an important source of guidance for AHF care. Thus, we convened 
an international group of practising emergency physicians, cardiologists and advanced practice nurses with the following 
goals to improve outcomes for AHF patients who present to the emergency department or other acute care setting 
through: (a) a better understanding of the pathophysiology, presentation and management of the initial phase of AHF 
care; (b) improving initial management by addressing knowledge gaps between best practices and current practice 
through education and research; and (c) to establish a framework for future emergency department-based international 
education and research.
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Introduction
Emergency departments (EDs) are a major entry point for 
the initial management of acute heart failure (AHF) patients 
throughout the world. Once in the ED, few AHF patients 
are discharged within 4–6 hours of initial evaluation,1–5 
marking an inflection point in a heart failure patient’s tra-
jectory. Once hospitalised, mortality rates are significantly 
higher compared to non-hospitalised patients.6,7
The initial diagnosis, management and disposition – the 
decision to admit or discharge – of AHF patients in the ED 
has significant downstream implications. Misdiagnosis, 
under or overtreatment, or inappropriate admission may 
place patients at increased risk for adverse events, and add 
costs to the healthcare system. Despite the critical impor-
tance of initial management, data are sparse regarding the 
impact of early AHF treatment delivered in the ED com-
pared to inpatient or chronic heart failure management.
The current state of AHF treatment is best summarised 
by guidelines; at the present time, no therapies for AHF 
receive a level of evidence A or ‘best evidence’ recom-
mendation. Furthermore, most guidelines focus on inpa-
tient management. The lack of evidence has led to a wide 
range of opinions, some with more supportive data than 
others, from a diuretic-sparing approach emphasising 
intravenous angiotensin-converting enzyme inhibitors or 
nitrates for vasodilation to a seemingly contradictory 
high-dose diuretic strategy. Although both approaches 
may be correct for specific AHF patients, practising clini-
cians would benefit from a description of an evidence-
based comprehensive approach combined with expert 
consensus to ED AHF care.
Outcomes from AHF are dismal.1,8,9 While some 
improvements have been made, these achievements have 
come through improved quality of care and adherence to 
existing chronic heart failure evidence, not through novel 
therapies.10 Nearly a third of patients hospitalised with 
AHF will be dead or re-hospitalised within 3 months after 
discharge.11,12 Within 1 year, 25–50% of patients will have 
died.13 The poor outcomes for AHF patients stands in 
marked contrast to the progress made in other cardiovascu-
lar fields.14,15 There continues to be over a million hospitali-
sations with a primary diagnosis of AHF in the USA, with 
comparable numbers in Europe.9,16 Heart failure is the most 
expensive reason for admission and re-admission in the 
USA for older patients.17 As the population continues to age 
and patients live longer with other cardiovascular diseases, 
this burden will continue to rise.18
In the absence of robust research evidence, consensus is 
an important source of guidance for AHF care.19 Thus, we 
convened an international group of practising emergency 
physicians, cardiologists and advanced practice nurses in 
December of 2013 and 2014. Our goal is to improve out-
comes for AHF patients who present to the ED or other 
acute care setting through: (a) a better understanding of the 
pathophysiology, presentation and management of the ini-
tial phase of AHF care; (b) improving initial management 
by addressing knowledge gaps between best practices and 
current practice through education and research; and (c) to 
establish a framework for future ED-based international 
education and research.
AHF in the ED setting
Patients presenting to the ED with AHF primarily com-
plain of dyspnoea, with multiple other signs and symptoms 
of heart failure.20,21 However, not all dyspnoea is AHF. 
Nearly 7.4% of all non-traumatic ED admissions present 
with dyspnoea, which are associated with a mortality rate 
of 9.4%. For those non-traumatic dyspnoeic patients 
admitted to the hospital, only 16.1% had the discharge 
diagnosis ‘heart failure’, highlighting the diversity of ED 
patients and the diagnostic challenges.22 Registries provide 
the broadest perspective of patients with AHF who present 
to the ED.
Although a large comorbid burden, including coronary 
artery disease, hypertension, diabetes and atrial fibrilla-
tion, is commonplace, there is tremendous heterogeneity 
regarding baseline characteristics of AHF patients, as 
shown by several registries (Table 1).13,23–25 While most 
patients have typical signs and symptoms of AHF, a size-
able proportion do not have rales, peripheral oedema, or 
jugular venous distention. Overall, it is difficult to create 
a prototypical AHF patient constructed from various reg-
istries, studies and administrative data. Despite the breadth 
and power of registry data, they also include patients 
directly admitted or transferred from outside hospitals, 
and with much of the data collected after the initial work-
up. This may be less applicable to the emergent setting. 
Moreover, registries usually do not include patients who 
have another major diagnosis such as pneumonia, sepsis 
or acute myocardial infarction and therefore are not pri-
marily classified as ‘heart failure’ patients. In contrast to 
the wide variation in clinical profiles, treatment is remark-
ably uniform; most patients receive intravenous diuretics, 
oxygen and little else (Figure 1), highlighting the rela-
tively weak therapeutic armamentarium in this field. The 
lack of a clear definition that accommodates the wide 
variety of patient profiles and presentations hinders both 
treatment and research. While there are common features, 
focusing on typical patient characteristics ignores a sub-
stantial subset of patients.
The major limitation of hospital registries is the absence 
of data on AHF patients discharged directly. Thus, the char-
acteristics of patients who are discharged from the ED are 
less well known, especially subsequent outcomes. Although 
a significant portion of patients may be safe for discharge 
from the ED,26,27 administrative database studies suggest that 
EDs may not discriminate well who is safe for discharge.3
 by guest on September 26, 2016acc.sagepub.comDownloaded from 
Pang et al. 3
Ta
bl
e 
1.
 A
cu
te
 h
ea
rt
 fa
ilu
re
 r
eg
is
tr
ie
s.
St
ud
y
A
D
H
ER
E1
A
D
H
ER
E-
EM
2
O
PT
IM
IZ
E-
H
F3
AT
T
EN
D
4
A
H
EA
D
5
RO
-A
H
FS
6
EH
FS
 II
7
ES
C
 H
F 
pi
lo
t8
A
LA
R
M
-
H
F9
IN
-H
F1
0
It
al
ia
n 
S1
1
O
FI
C
A
12
C
an
ad
ia
n 
C
oh
or
t 
St
ud
y1
3 *
R
IC
A
14
EA
H
FE
15
Ep
id
em
io
lo
gy
C
ou
nt
ry
U
SA
U
SA
U
SA
Ja
pa
n
C
ze
ch
 
R
ep
ub
lic
R
om
an
ia
Eu
ro
pe
Eu
ro
pe
Eu
ro
pe
, 
T
ur
ke
y,
 
A
us
tr
al
ia
, 
M
ex
ic
o
It
al
y
It
al
y
Fr
an
ce
C
an
ad
a
Sp
ai
n
Sp
ai
n
N
um
be
r 
of
 
pa
rt
ic
ip
at
in
g 
ce
nt
re
s
27
4
83
25
9
32
7
13
13
3
13
6
66
8
61
20
6
17
0
86
52
29
Y
ea
r 
of
 t
he
 
st
ud
y 
(m
on
th
s 
of
 in
cl
us
io
n)
20
01
–4
 (
36
)
20
04
–5
 (
21
)
20
03
–4
 (
22
)
20
07
–9
 (
27
)
20
06
–9
 (
38
)
20
08
–9
 (
12
)
20
04
–5
 (
10
)
20
09
–1
0 
(8
)
20
06
–7
 (
6)
20
07
–9
 (
23
)
20
04
 (
3)
20
09
 (
1 
dí
a)
20
04
–7
 (
36
)
20
08
–9
 (
10
)
20
07
–1
1 
(4
)
T
yp
e 
of
 s
tu
dy
R
R
R
P
R
P
P
P
R
P
P
P
R
P
P
Se
tt
in
g
H
os
p.
H
ED
H
os
p.
H
os
p.
H
os
p.
/C
ar
d.
H
os
p.
/C
ar
d.
H
os
p.
H
os
p.
/C
ar
d.
H
os
p.
H
os
p.
 /C
ar
d.
H
os
p.
/C
ar
d.
H
os
p.
/C
ar
d.
H
ED
H
os
p.
/IM
H
ED
N
um
be
r 
of
 p
at
ie
nt
s 
in
cl
ud
ed
10
53
88
10
98
4
48
61
2
28
67
41
53
32
24
35
80
18
92
49
53
18
55
28
07
16
48
12
59
1
11
72
58
45
A
ge
, y
ea
rs
, 
m
ea
n 
(S
D
)
72
 (
14
)
73
 (
14
)
73
 (
14
)
73
 (
14
)
71
 (
12
)
69
 (
22
)
71
 (
N
A
)
70
 (
13
)
66
–7
0
70
 (
13
)
73
 (
11
)
76
 (
13
)
75
 (
11
)
7 
(8
)
79
 (
10
)
W
om
en
 (
%
)
52
52
.2
52
41
42
.4
44
39
37
62
.4
40
39
.5
46
48
.5
54
.9
56
.5
Fo
rm
 o
f p
re
se
nt
at
io
n
C
ar
di
og
en
ic
 
sh
oc
k 
(%
)
N
A
N
A
N
A
N
A
14
.5
5
4
2
11
.7
2
7.
7
6
N
A
N
A
0.
7
A
cu
te
 
pu
lm
on
ar
y 
oe
de
m
a 
(%
)
N
A
N
A
N
A
N
A
18
.4
29
16
N
A
36
.7
27
49
.6
38
N
A
N
A
11
R
ig
ht
 C
I (
%
)
N
A
N
A
N
A
N
A
3.
8
4
3
N
A
4.
5
9
N
A
6
N
A
N
A
2.
6
A
cu
te
 
co
ro
na
ry
 
sy
nd
ro
m
e 
(%
)
N
A
N
A
N
A
N
A
36
.2
11
.3
30
N
A
36
.9
13
33
13
N
A
N
A
2.
8
In
fe
ct
io
n 
tr
ig
ge
ri
ng
 
fa
ct
or
 (
%
)
N
A
N
A
15
N
A
N
A
N
A
17
.6
N
A
16
.3
N
A
N
A
27
N
A
N
A
32
.1
Ph
ys
ic
al
 a
nd
 la
bo
ra
to
ry
 fi
nd
in
gs
M
ea
n 
SB
P 
(m
m
H
g)
14
4
N
A
14
3
14
7
13
5
14
3
13
5
13
3
13
0 
(d
eb
ut
) 
13
0 
(c
ró
ni
ca
)
13
4
14
1
13
0
14
6
N
A
14
2
M
ea
n 
H
R
 
(b
pm
)
N
A
89
87
99
90
98
95
88
10
7 
(c
ró
ni
ca
) 
11
0 
(d
eb
ut
)
93
97
89
89
N
A
90
M
ea
n 
cr
ea
tin
in
e 
(m
g/
dl
)
1.
8
1.
8
1.
8
1.
4
1.
2
1.
3
N
A
N
A
N
A
1.
5
1.
7
1.
5
0.
76
N
A
1.
3
(C
on
tin
ue
d)
 by guest on September 26, 2016acc.sagepub.comDownloaded from 
4 European Heart Journal: Acute Cardiovascular Care 
St
ud
y
A
D
H
ER
E1
A
D
H
ER
E-
EM
2
O
PT
IM
IZ
E-
H
F3
AT
T
EN
D
4
A
H
EA
D
5
RO
-A
H
FS
6
EH
FS
 II
7
ES
C
 H
F 
pi
lo
t8
A
LA
R
M
-
H
F9
IN
-H
F1
0
It
al
ia
n 
S1
1
O
FI
C
A
12
C
an
ad
ia
n 
C
oh
or
t 
St
ud
y1
3 *
R
IC
A
14
EA
H
FE
15
A
na
em
ia
 (
%
)
N
A
N
A
N
A
N
A
35
.1
‡
N
A
14
.7
¶
31
.4
§
14
.4
¶
38
.7
§
46
§
N
A
N
A
45
.1
§
57
.1
‡
H
yp
on
at
re
m
ia
 
(%
)
N
A
N
A
N
A
N
A
5*
*
N
A
N
A
N
A
N
A
18
.8
~
45
~
N
A
N
A
N
A
5.
9*
*;
 2
0.
8~
BN
P 
pe
rf
or
m
ed
 
(%
)
63
N
A
8
N
A
N
A
N
A
16
37
N
A
30
N
A
82
N
A
N
A
34
M
ea
n 
LV
EF
 
(%
)
34
38
39
N
A
37
38
38
38
40
 (
de
bu
t)
 
37
 
(c
ró
ni
ca
)
38
37
42
N
A
50
50
T
re
at
m
en
t 
of
 t
he
 a
cu
te
 e
pi
so
de
N
IV
 (
%
)
N
A
N
A
N
A
36
.1
8.
9
N
A
13
.9
N
A
9.
6
N
A
N
A
12
.4
N
A
N
A
6.
4
D
iu
re
tic
s 
(%
)
N
A
N
A
N
A
80
.4
N
A
80
84
.4
84
.6
89
.7
99
95
.3
N
A
N
A
N
A
96
.8
V
as
od
ila
to
rs
 
(%
)
21
N
A
14
.3
45
.8
N
A
33
38
.7
18
.5
41
.1
29
.9
51
.3
N
A
N
A
N
A
20
.7
In
ot
ro
pe
s 
(%
)
15
N
A
10
.9
20
.7
22
.3
18
29
.8
10
.5
39
19
.4
24
.6
13
.8
N
A
N
A
2.
1
O
ut
co
m
e
H
os
pi
ta
l 
st
ay
 (
da
ys
) 
m
ed
ia
n/
m
ea
n
4.
3/
N
A
N
A
/N
A
4/
5.
7
21
/3
1
7.
1/
N
A
N
A
/8
.4
N
A
/9
N
A
/N
A
6/
N
A
10
/N
A
9/
N
A
13
/N
A
N
A
/N
A
N
A
/N
A
7/
9.
4
A
dm
is
si
on
 in
 
th
e 
IC
U
 (
%
)
18
.7
N
A
N
A
N
A
N
A
N
A
51
48
17
51
.9
69
43
N
A
N
A
1.
9
In
ho
sp
ita
l 
m
or
ta
lit
y 
(%
)
4
5.
8
3.
8
7.
7
12
.7
7.
7
7.
3
3.
8
17
.8
6.
4
7.
3
8.
2
N
A
†
N
A
7.
6
A
cu
te
 h
ea
rt
 fa
ilu
re
 r
eg
is
tr
ie
s.
 R
ep
ro
du
ce
d 
fr
om
 E
M
ER
G
EN
C
IA
S 
w
ith
 p
er
m
is
io
n 
of
 t
he
 p
ub
lis
he
rs
 (
5)
. R
ef
er
en
ce
s 
ca
n 
be
 r
et
ri
ev
ed
 fr
om
 t
he
 o
ri
gi
na
l p
ub
lic
at
io
n.
R
: r
et
ro
sp
ec
tiv
e;
 P
: p
ro
sp
ec
tiv
e;
 H
os
p.
: h
os
pi
ta
lis
ed
; C
ar
d.
: c
ar
di
ol
og
y;
 H
ED
: h
os
pi
ta
l e
m
er
ge
nc
y 
de
pa
rt
m
en
t; 
C
O
PD
: c
hr
on
ic
 o
bs
tr
uc
tiv
e 
pu
lm
on
ar
y 
di
se
as
e;
 C
I: 
ca
rd
ia
c 
in
su
ffi
ci
en
cy
; A
C
EI
/A
R
Bs
: a
ng
io
te
ns
in
-c
on
ve
rt
in
g 
en
zy
m
e 
 
in
hi
bi
to
r/
an
gi
ot
en
si
n-
II 
an
ta
go
ni
st
; L
V
EF
: l
ef
t 
ve
nt
ri
cu
la
r 
ej
ec
tio
n 
fr
ac
tio
n;
 S
BP
: s
ys
to
lic
 b
lo
od
 p
re
ss
ur
e;
 H
R
: h
ea
rt
 r
at
e;
 B
N
P:
 n
at
ri
ur
et
ic
 p
ep
tid
es
; N
IV
: n
on
-in
va
si
ve
 v
en
til
at
io
n;
 IC
U
: i
nt
en
si
ve
 c
ar
e 
un
it;
 IM
: i
nt
er
na
l m
ed
ic
in
e.
*T
he
 d
at
a 
w
er
e 
ob
ta
in
ed
 fr
om
 t
he
 s
um
 o
f t
he
 c
oh
or
t 
de
ri
va
tio
n 
an
d 
va
lid
at
io
n 
co
ho
rt
.
† M
or
ta
lit
y 
at
 7
 d
ay
s:
 2
%
.
‡ H
ae
m
og
lo
bi
n 
<
12
 in
 w
om
en
 a
nd
 <
13
 g
/d
l i
n 
m
en
.
§H
ae
m
og
lo
bi
n 
<
 2
 g
/d
l.
¶L
im
it 
no
t 
av
ai
la
bl
e.
**
So
di
um
 <
13
0 
m
m
Eq
/l.
~
So
di
um
 <
13
6 
m
m
Eq
/l.
∞
C
hr
on
ic
 d
ia
ly
si
s.
ˇE
st
im
at
ed
 g
lo
m
er
ul
ar
 fi
ltr
at
io
n 
ra
te
 <
60
 m
l/m
in
.
ˆM
ed
ic
at
io
n 
at
 d
is
ch
ar
ge
.
¥D
at
a 
ob
ta
in
ed
 fr
om
 a
 s
ub
st
ud
y.
Ta
bl
e 
1.
 (
C
on
tin
ue
d)
 by guest on September 26, 2016acc.sagepub.comDownloaded from 
Pang et al. 5
Initial approach to the ED patient 
with suspected AHF
Patients present to the ED with signs and symptoms, not 
diagnoses. Thus, the initial approach to AHF patients starts 
with a signs and symptoms, chief complaint-based approach 
(see Figure 2). When faced with a patient in respiratory dis-
tress, the challenges of making a rapid diagnosis of AHF 
become readily apparent: (a) shortness of breath is a symp-
tom common to other pathologies; (b) the myriad precipi-
tants and mechanisms that lead to AHF may not be 
immediately identifiable; (c) heart failure patients are 
multi-morbid, with many acute as well as chronic comorbid 
conditions that may obfuscate the clinical picture; (d) heart 
failure patients are older and often frail, and may require 
more time to elicit the reasons for decompensation, such as 
self-care and caregiver status; (e) there is time pressure to 
disposition patients rapidly due to the large volume of 
undifferentiated patients waiting to be seen; (f) the burden 
of AHF disproportionately impacts those in the lower soci-
oeconomic status groups, thus more resources may be 
needed for both assessment and assistance than is possible 
in a brief ED intervention; both psychosocial and socioeco-
nomic factors limit adherence to treatment and compli-
ance;28 (g) there continues to be an unmet need for valid 
and facile risk stratification instruments.1,27,29,30 Therefore, 
the use of well-structured decision-making algorithms is 
essential to optimise the management of patients with sus-
pected AHF in the ED. These should incorporate guidance 
for both ruling out and treating life-threatening conditions 
initially, with guidance to facilitate accurate diagnosis with 
an appropriate differential diagnosis (Figure 2).
For treatment of the AHF patient, we advocate for edu-
cation centred on a phenotype/precipitant approach. This 
algorithm begins with the undifferentiated patient who pre-
sents with a chief complaint, not a diagnosis, consistent 
with current emergency medicine practice. First, whether 
or not the patient requires immediate intervention is 
addressed. Once stable enough for a more traditional his-
tory and physical examination, the patient is then classified 
based on easily measureable phenotypic characteristics, 
with treatment directed towards that classification. 
Importantly, diagnostic and therapeutic plans commonly 
occur in parallel, unlike a traditional medical encounter in 
which actions occur in series. Finally, diagnostic uncer-
tainty is directly addressed; frequent re-assessment and re-
evaluation is emphasised to ensure patients are improving.
Differences in emergency care 
settings
We acknowledge that emergency care differs throughout 
the world, compounding the challenges of ED AHF man-
agement. Usually patients cluster according to the local 
geography of their hospitals. Resource limitations, educa-
tional background and specialisation of physicians and 
nurses appear to be very important for clinical out-
comes.31–33 The specialty of emergency medicine itself is 
most well established in the USA, yet it is only 50 years 
old. In many countries, there is no specialty of emergency 
medicine. We also acknowledge that in many countries, 
EDs function as safety nets for healthcare – the place to go 
when there is no other place to go, when time is of the 
essence, or for when office-based practices are not open, 
Figure 1. Intravenous therapies from 3 different registries. 
ADHERE: acute decompensated heart failure registry; Dobut: dobutamine; Dopa: dopamine; EHFS-II: euroheart failure survey 2; Lev: levosimendan; 
Mil: milrinone; Nesir: nesiritide; NTG: nitroglycerin.
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such as nights, weekends and holidays. For these reasons, 
we believe that education through a case-based learning 
approach may be particularly appropriate for improving the 
management of AHF in the emergency care setting.
Future directions
Ideally, future educational efforts will bridge research and 
education (Table 2). As more knowledge accumulates, 
more robust recommendations will be provided. Simulated 
patient cases will continue to be developed, as repetition 
combined with variations of common AHF presentations 
will strengthen clinical management. This is especially 
important given continuing evidential uncertainties. A 
brief overview of future directions will be covered below.
Risk-stratification is a major focus of our consensus 
group, as the decision to admit or discharge from the ED 
has significant downstream implications. At present, the 
vast majority of patients are admitted.1 While several risk 
scores have been developed, none are widely used due to 
either validation, discrimination, calibration or ease of use 
issues.26 Nevertheless, strategies to improve discharge 
decision-making should be developed, as proved by strate-
gies to reduce readmissions for heart failure patients admit-
ted to the ward.34 This includes innovative strategies of 
care, such as observation medicine for heart failure or com-
munity paramedicine with trained paramedics visiting 
patients after an ED or hospital visit. 
The ED plays a role in the prevention of heart failure or 
maintenance of guideline therapy. While this may be ini-
tially counterintuitive, patients with chronic conditions 
may present for other reasons. For example, a heart failure 
patient may present with gout, or a stage B patient may 
present with a laceration. Such encounters present potential 
opportunities to partner with nursing homes, extended care 
and skilled nursing facilities, advanced practice providers, 
primary care physicians (including comprehensive primary 
care models, i.e. ‘medical home’), cardiologists and other 
multidisciplinary stakeholders. Rather than view the ED as 
a single transaction, there is ample opportunity to partici-
pate in the overall care of patients.
As highlighted above, there is a lack of data concerning 
details of current clinical practice of AHF management in the 
ED as well as evidence-based therapies. Novel therapies are 
Figure 2. Initial Approach to the AHF Patient.
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currently being tested as well as approaches to diagnosis, risk 
stratification and strategies of care. It is also worth highlight-
ing the ongoing development of novel biomarkers that will 
aid not only current management, but shed light on the patho-
physiology of AHF. Particularly relevant to the ED is organ 
injury. Whether prevention or protection from organ injury 
will lead to improved outcomes is an active area of investiga-
tion. Organ injury may be time dependent, suggesting a need 
for early intervention.35,36 As portable bedside ultrasound (to 
distinguish from detailed echocardiography) continues to 
becomes more widespread in the ED, a more direct focus on 
cardiac structure, function and haemodynamics may occur. 
Some centres already perform detailed echocardiography 
assessments of ED patients with AHF. Other imaging modali-
ties or approaches, such as lung ultrasound, are likely to 
become more widely used. If current research endeavours are 
successful, integration into existing algorithms as well as new 
approaches to AHF may be needed. Given the burden of AHF 
and the role the ED plays in AHF management, dissemination 
regarding appropriate use will be critical.
Conclusions
The lack of evidence regarding the initial management of 
patients with AHF, continued poor outcomes and limited 
therapeutic advances highlight the challenges facing clini-
cians caring for AHF patients in the ED. At the same time, 
EDs do not operate in isolation. Their ability to manage 
chronic diseases during an acute exacerbation, as well as 
integrate into an overall episode of care, are critical opera-
tional considerations and important to the health of an over-
all system of care. The prevalence of heart failure and the 
dominance of the ED as an entry point for admissions pre-
sent a unique opportunity to challenge traditional perspec-
tives of emergency care as a contributor to the overuse of 
healthcare resources, instead envisioning the ED as a potent 
partner in the overall management of heart failure.
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